Blocking an inflammatory protein slows the pace of ageing

Mice live longer and healthier lives when a cytokine protein called IL-11 is

Researchers from the Buck Institute for Research on Aging and Stanford University have discovered that blocking an inflammatory protein called IL-11 in middle-aged mice boosted metabolism, reduced frailty, and increased lifespan by about 25%.

The findings, published in the journal Nature Metabolism, show how researchers can move beyond broad generalizations to engage with the nuances that modulate the pace of ageing.

“Ageing is not a disease, but it is the biggest risk factor for most chronic diseases,” said Judith Campisi, PhD, a professor at the Buck Institute and senior author of the study. “We need to understand the mechanisms that drive ageing so that we can develop interventions to slow it down and improve the healthspan of older adults.”

IL-11 is a cytokine, a type of protein that is involved in inflammation. Inflammation is a natural response to injury or infection, but chronic inflammation can damage tissues and organs and contribute to ageing.

In the study, the researchers used a drug called losmapimod to block IL-11 in middle-aged mice. Losmapimod is an investigational compound that is being developed for the treatment of inflammatory diseases.

The researchers found that losmapimod treatment improved the health and lifespan of the mice. The mice had increased energy levels, improved muscle function, and reduced frailty. They also lived about 25% longer than untreated mice.

The researchers believe that losmapimod’s effects are due to its ability to block IL-11. IL-11 is known to promote inflammation and inhibit metabolism. By blocking IL-11, losmapimod may be able to slow down the ageing process.

“Our findings suggest that targeting IL-11 may be a promising strategy for slowing ageing and improving the healthspan of older adults,” said Campisi.